Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer;Quimioterapia sistémica basada en docetaxel en hombres coreanos mayores con cáncer de próstata resistente a la castración

Actas Urologicas Espanolas

Volumn 36, Issue 7, 2012, Pages 425-430

  Park, S C H ^a   Whan, L J ^a   Sik, R J ^a  

^a Escuela Universitaria de Medicina y Hospital de Wonkwan   (South Korea)

Author keywords

Chemotherapy; Prostate neoplasm; Safety

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; TAXOID;

AGE; AGED; ARTICLE; ASIAN; COMPARATIVE STUDY; DRUG RESISTANCE; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84861585181     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2011.09.008     Document Type: Article

References (18)

1. Ministry of Health and Welfare Republic of Korea 2008 Annual Report of the Korean Central Cancer Registry 2008 Ministry of Health and Welfare Republic of Korea Seoul
2. E. Duthie Physiology of age: Relevance to symptoms, perceptions, and treatment tolerance L. Balducci, G.H. Lyman, W.B. Ershler, Comprehensive Geriatric Oncology 2004 Taylor and Francis London 207 223
3. L. Balducci, H.J. Cohen, P.F. Engtrom, D.S. Ettinger, J. Halter, and L.I. Gordon Senior adult oncology clinical practice guidelines in oncology J Natl Compr Canc Netw 3 2005 572 590 (Pubitemid 44265430)
4. R. De Witt Chemotherapy in hormone-refractory prostate cancer BJU Int 101 Suppl. 2 2008 11 15
5. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, and K.N. Chi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
6. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N Lara Jr., J.A. Jones, and M.E. Taplin Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
7. J.Y. Joung, I.G. Jeong, K.S. Han, T.S. Kim, S.O. Yang, and H.K. Seo Docetaxel chemotherapy of Korean patients with hormone-refractory prostate cancer: comparative analysis between 1st-line and 2nd-line docetaxel Yonsei Med J 49 2008 775 782
8. J.L. Lee, J.E. Kim, J.H. Ahn, D.H. Lee, C.S. Kim, and J.H. Hong Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: Single institutional study in Korea Cancer Res Treat 42 2010 12 17
9. A. Italiano, C. Ortholan, S. Oudard, D. Poussel, G. Gravis, and P. Beuzeboc Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer Eur Urol 55 2009 1368 1376
10. H.I. Scher, M. Eisenberger, A.V. D'Amico, S. Halabi, E.J. Small, and M. Morris Eligibility and outcomes reporting guidelines for clinical trials for patients in the stage of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Groups J Clin Oncol 22 2004 537 556 (Pubitemid 41079783)
11. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solids tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. S.F. Shariat, M. Milowsky, and M.J. Droller Bladder cancer in the elderly Urol Oncol 27 2009 653 667
13. J.A. Meyerhardt, J.E. Tepper, D. Niedzwiecku, D.R. Hollis, A.D. McCollum, and D. Brady Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114 J Clin Oncol 22 2004 648 657 (Pubitemid 41095068)
14. I. Carreca, and L. Balducci Cancer chemotherapy in the older cancer patient Urol Oncol 27 2009 633 642
15. C. Jagger, R. Matthews, F. Matthews, T. Robinson, J.M. Robine, and C. Brayne Medical Research Council Cognitive Function and Aging Study Investigators. The burden of diseases on disability-free life expectancy in late life J Gerontol A Biol Sci Med Sci 62 2007 408 414
16. S.M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, and V.A. Morrison International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients - an analysis of the medical literatures J Clin Oncol 25 2007 1832 1843 (Pubitemid 46860272)
17. A. Ten Tije, J. Verweij, M.A. Carducci, W. Graveland, T. Rogers, and T. Pronk Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly J Clin Oncol 23 2005 1070 1077 (Pubitemid 46202261)
18. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX327 study J Clin Oncol 26 2008 242 245